DK1862802T3 - Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70 - Google Patents

Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70

Info

Publication number
DK1862802T3
DK1862802T3 DK06011409T DK06011409T DK1862802T3 DK 1862802 T3 DK1862802 T3 DK 1862802T3 DK 06011409 T DK06011409 T DK 06011409T DK 06011409 T DK06011409 T DK 06011409T DK 1862802 T3 DK1862802 T3 DK 1862802T3
Authority
DK
Denmark
Prior art keywords
zap
aminopyrido
pyrimidine ligand
complex
phosphorylated zap
Prior art date
Application number
DK06011409T
Other languages
English (en)
Inventor
Ulrich Kruse
Nigel Ramsden
Gerard Drewes
Dirk Eberhard
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of DK1862802T3 publication Critical patent/DK1862802T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
DK06011409T 2006-06-01 2006-06-01 Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70 DK1862802T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011409A EP1862802B1 (en) 2006-06-01 2006-06-01 Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70

Publications (1)

Publication Number Publication Date
DK1862802T3 true DK1862802T3 (da) 2009-04-14

Family

ID=37075506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06011409T DK1862802T3 (da) 2006-06-01 2006-06-01 Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70

Country Status (12)

Country Link
US (1) US20120178180A1 (da)
EP (1) EP1862802B1 (da)
JP (1) JP4987970B2 (da)
CN (1) CN101490557B (da)
AT (1) ATE417274T1 (da)
AU (1) AU2007267291B2 (da)
CA (1) CA2653760A1 (da)
DE (1) DE602006004196D1 (da)
DK (1) DK1862802T3 (da)
ES (1) ES2318616T3 (da)
HK (1) HK1115632A1 (da)
WO (1) WO2007137867A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5181908B2 (ja) * 2008-08-04 2013-04-10 株式会社島津製作所 質量分析データ解析装置
EP2419423A1 (en) 2009-04-14 2012-02-22 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
MX2012004020A (es) 2009-10-20 2012-05-08 Cellzome Ltd Analogos de heterociclilo pirazolopirimidina como inhibidores de jak.
SG184989A1 (en) 2010-04-30 2012-11-29 Cellzome Ltd Pyrazole compounds as jak inhibitors
EP2574194B1 (en) * 2010-05-21 2017-10-11 University of Florida Research Foundation, Inc. Macrocyclic compounds for use in the treatment of osteoporosis
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012022681A2 (en) 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
KR20140047092A (ko) 2011-07-28 2014-04-21 셀좀 리미티드 Jak 억제제로서의 헤테로시클릴 피리미딘 유사체
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
AU2012357038B2 (en) 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
EP2855451B1 (en) 2012-05-24 2017-10-04 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
CN108088998B (zh) * 2016-11-23 2019-12-27 四川大学华西医院 一种肺癌筛查试剂盒
CN113030359A (zh) * 2021-01-28 2021-06-25 成都第一制药有限公司 一种益母草注射液中多种指标成分的检测方法及益母草注射液的质量控制方法
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
DK1250155T3 (da) * 1999-12-22 2008-08-25 Scripps Research Inst Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet
US20050064510A1 (en) * 2003-03-10 2005-03-24 Akyuz Can D. Ligand analysis
EP2233174B1 (en) * 2004-01-21 2016-07-20 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
WO2005123048A2 (en) * 2004-06-21 2005-12-29 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
WO2006134056A1 (en) * 2005-06-14 2006-12-21 Cellzome Ag Process for the identification of novel enzyme interacting compounds
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US8268809B2 (en) * 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity

Also Published As

Publication number Publication date
JP4987970B2 (ja) 2012-08-01
EP1862802A1 (en) 2007-12-05
JP2009539081A (ja) 2009-11-12
AU2007267291A1 (en) 2007-12-06
DE602006004196D1 (de) 2009-01-22
ES2318616T3 (es) 2009-05-01
ATE417274T1 (de) 2008-12-15
CA2653760A1 (en) 2007-12-06
CN101490557A (zh) 2009-07-22
US20120178180A1 (en) 2012-07-12
AU2007267291B2 (en) 2013-09-12
CN101490557B (zh) 2013-08-21
WO2007137867A1 (en) 2007-12-06
EP1862802B1 (en) 2008-12-10
HK1115632A1 (en) 2008-12-05

Similar Documents

Publication Publication Date Title
DK1862802T3 (da) Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70
DK1887359T3 (da) Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K
Kukurugya et al. Multi-omics analysis unravels a segregated metabolic flux network that tunes co-utilization of sugar and aromatic carbons in Pseudomonas putida
WO2001027624A3 (en) Compositions and methods for detecting protein modification and enzymatic activity
WO2003039483A3 (en) An enzyme-based system and sensor for measuring acetone
Wei et al. Deep coverage proteomics identifies more low-abundance missing proteins in human testis tissue with Q-exactive HF mass spectrometer
MX2009013411A (es) Deteccion de antigenos transportados por eritrocitos y de anticuerpos anti-eritrocitos.
DK1105360T3 (da) Identifikation af forbindelse-protein-interaktioner ved anvendelse af biblioteker af protein-nukleinsyrefusionsmolekyler
WO2005116643A3 (en) Identification of compounds modifying a cellular response
ATE545460T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
ATE452208T1 (de) Verfahren zum nachweis einer zielsubstanz unter verwendung einer nukleinsäuresonde
Cao et al. An integrated analysis of metabolites, peptides, and inflammation biomarkers for assessment of preanalytical variability of human plasma
WO2009007719A3 (en) Detection of micro-organisms based on their nad-dependent dna ligase activity
ATE516363T1 (de) Generischer kinase-/phosphatasetest mit einzelablesung
Lefkowitz et al. An electrophoretic method for the detection of chymotrypsin and trypsin activity directly in whole blood
WO2006020766A3 (en) Point source diffusion cell activity assay apparatuses and methods
WO2010056681A3 (en) Thyroid analyte detection and measurement
SG148027A1 (en) Methods for identifying combinations of entities as therapeutics
Bulfer et al. Crystal structure and functional analysis of homocitrate synthase, an essential enzyme in lysine biosynthesis
Gevaert et al. Applications of diagonal chromatography for proteome‐wide characterization of protein modifications and activity‐based analyses
Wang et al. Four-Dimensional Orthogonal Electrophoresis System for Screening Protein Complexes and Protein− Protein Interactions Combined with Mass Spectrometry
DE60034880D1 (de) Ceramidasegen
Sprout et al. Using enzyme inhibition as a high throughput method to measure the enantiomeric excess of a chiral sulfoxide
ATE364172T1 (de) Messzelle
Botzen et al. Degradation of HNE-modified proteins–possible role of ubiquitin